TAS 109Alternative Names: TAS-109
Latest Information Update: 24 Aug 2010
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Nucleosides
- Mechanism of Action DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Colorectal cancer